Cargando…

Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada

AmpC β-lactamase, altered porins, or both are usually responsible for cefoxitin resistance in Escherichia coli. We examined the relative importance of each. We studied 18 strains of clinical isolates with reduced cefoxitin susceptibility and 10 initially-susceptible strains passaged through cefoxiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Clarke, Brian, Hiltz, Margot, Musgrave, Heather, Forward, Kevin R.
Formato: Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033074/
https://www.ncbi.nlm.nih.gov/pubmed/14609460
http://dx.doi.org/10.3201/eid0910.030093
_version_ 1782197533457514496
author Clarke, Brian
Hiltz, Margot
Musgrave, Heather
Forward, Kevin R.
author_facet Clarke, Brian
Hiltz, Margot
Musgrave, Heather
Forward, Kevin R.
author_sort Clarke, Brian
collection PubMed
description AmpC β-lactamase, altered porins, or both are usually responsible for cefoxitin resistance in Escherichia coli. We examined the relative importance of each. We studied 18 strains of clinical isolates with reduced cefoxitin susceptibility and 10 initially-susceptible strains passaged through cefoxitin-gradient plates. Of 18 wild-resistant strains, 9 had identical promoter mutations (including creation of a consensus 17-bp spacer) and related pulsed-field gel electrophoresis patterns; the other 9 strains were unrelated. Nine strains had attenuator mutations; two strains did not express OmpC or OmpF. After serial passage, 8 of 10 strains developed cefoxitin resistance, none developed promoter or attenuator mutations, 6 lost both the OmpC and OmpF porin proteins, and 1 showed decreased production of both. One strain had neither porin alteration or increased AmpC production. Porin mutants may occur more commonly and be less fit and less inclined to spread or cause disease than strains with increased β-lactamase expression.
format Text
id pubmed-3033074
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-30330742011-02-09 Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada Clarke, Brian Hiltz, Margot Musgrave, Heather Forward, Kevin R. Emerg Infect Dis Research AmpC β-lactamase, altered porins, or both are usually responsible for cefoxitin resistance in Escherichia coli. We examined the relative importance of each. We studied 18 strains of clinical isolates with reduced cefoxitin susceptibility and 10 initially-susceptible strains passaged through cefoxitin-gradient plates. Of 18 wild-resistant strains, 9 had identical promoter mutations (including creation of a consensus 17-bp spacer) and related pulsed-field gel electrophoresis patterns; the other 9 strains were unrelated. Nine strains had attenuator mutations; two strains did not express OmpC or OmpF. After serial passage, 8 of 10 strains developed cefoxitin resistance, none developed promoter or attenuator mutations, 6 lost both the OmpC and OmpF porin proteins, and 1 showed decreased production of both. One strain had neither porin alteration or increased AmpC production. Porin mutants may occur more commonly and be less fit and less inclined to spread or cause disease than strains with increased β-lactamase expression. Centers for Disease Control and Prevention 2003-10 /pmc/articles/PMC3033074/ /pubmed/14609460 http://dx.doi.org/10.3201/eid0910.030093 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research
Clarke, Brian
Hiltz, Margot
Musgrave, Heather
Forward, Kevin R.
Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada
title Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada
title_full Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada
title_fullStr Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada
title_full_unstemmed Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada
title_short Cephamycin Resistance in Clinical Isolates and Laboratory-derived Strains of Escherichia coli, Nova Scotia, Canada
title_sort cephamycin resistance in clinical isolates and laboratory-derived strains of escherichia coli, nova scotia, canada
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033074/
https://www.ncbi.nlm.nih.gov/pubmed/14609460
http://dx.doi.org/10.3201/eid0910.030093
work_keys_str_mv AT clarkebrian cephamycinresistanceinclinicalisolatesandlaboratoryderivedstrainsofescherichiacolinovascotiacanada
AT hiltzmargot cephamycinresistanceinclinicalisolatesandlaboratoryderivedstrainsofescherichiacolinovascotiacanada
AT musgraveheather cephamycinresistanceinclinicalisolatesandlaboratoryderivedstrainsofescherichiacolinovascotiacanada
AT forwardkevinr cephamycinresistanceinclinicalisolatesandlaboratoryderivedstrainsofescherichiacolinovascotiacanada